• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

镓和镥-奥曲肽在一例罕见的SSTR2和ESWR1-CREM融合阳性的肺未分化圆形细胞瘤中的成像与治疗

Imaging and treatment with Gallium and Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung.

作者信息

Kumaran Arjunan, Koo Si Xuan, Yeong Joe, Takano Angela Maria, Farid Mohamad, Loke Siu Hoong, Nei Wen Long

机构信息

Division of Radiation Oncology, National Cancer Centre, Singapore, Singapore.

Department of Nuclear Medicine & Molecular Imaging, Division of Radiological Sciences, Singapore General Hospital, Singapore, Singapore.

出版信息

BJR Case Rep. 2022 Nov 8;9(1):20220094. doi: 10.1259/bjrcr.20220094. eCollection 2023 Feb.

DOI:10.1259/bjrcr.20220094
PMID:36873236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9976727/
Abstract

The authors present a 45-year-old lady with a rare undifferentiated round cell tumour of the lung with a ESWR1-CREM fusion gene that progressed despite multiple lines of therapy. The tumour was Somatostatin Receptors Type 2 (SSTR2) positive and avid on Gallium-DOTATATE imaging. This allowed for novel treatment with Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium-DOTATATE after all other standard of care options were exhausted.

摘要

作者报告了一位45岁女性，患有罕见的肺未分化圆形细胞瘤，带有ESWR1-CREM融合基因，尽管接受了多线治疗仍进展。该肿瘤为2型生长抑素受体（SSTR2）阳性，在镓- DOTATATE显像上摄取良好。在所有其他标准治疗方案均无效后，这使得可以使用镥- DOTATATE进行肽受体放射性核素治疗（PRRT）的新型治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/193c139e7b4d/bjrcr.20220094.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/3d5a55770fe7/bjrcr.20220094.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/324338e20bb4/bjrcr.20220094.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/d56e2aac8e07/bjrcr.20220094.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/0175cfdbd426/bjrcr.20220094.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/8fdbe6eabccb/bjrcr.20220094.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/193c139e7b4d/bjrcr.20220094.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/3d5a55770fe7/bjrcr.20220094.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/324338e20bb4/bjrcr.20220094.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/d56e2aac8e07/bjrcr.20220094.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/0175cfdbd426/bjrcr.20220094.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/8fdbe6eabccb/bjrcr.20220094.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb89/9976727/193c139e7b4d/bjrcr.20220094.g006.jpg

相似文献

1
Imaging and treatment with Gallium and Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung.镓和镥-奥曲肽在一例罕见的SSTR2和ESWR1-CREM融合阳性的肺未分化圆形细胞瘤中的成像与治疗
BJR Case Rep. 2022 Nov 8;9(1):20220094. doi: 10.1259/bjrcr.20220094. eCollection 2023 Feb.
2
Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer.拓展新型治疗诊断用177Lu-奥曲肽肽受体放射性核素治疗的适应症：默克尔细胞癌中肽受体放射性核素治疗的概念验证
Case Rep Oncol. 2019 Jan 21;12(1):98-103. doi: 10.1159/000496335. eCollection 2019 Jan-Apr.
3
The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.基线 Ga-68 DOTATATE 正电子发射断层扫描/计算机断层扫描在预测 Lu-177 DOTATATE 固定剂量肽受体放射性核素治疗反应中的作用。
Turk J Med Sci. 2016 Feb 17;46(2):409-13. doi: 10.3906/sag-1412-11.
4
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?PRRT 治疗神经内分泌肿瘤的演变；接下来会怎样？
Front Endocrinol (Lausanne). 2022 Oct 31;13:941832. doi: 10.3389/fendo.2022.941832. eCollection 2022.
5
Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.病例报告：177 镥-DOTATATE 治疗转移性副神经节瘤相关原发性甲状腺功能减退症。
Front Endocrinol (Lausanne). 2021 Jan 21;11:587065. doi: 10.3389/fendo.2020.587065. eCollection 2020.
6
Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).肽受体放射性核素治疗（PRRT）在晚期转移性支气管神经内分泌肿瘤（NETs）中的疗效和耐受性。
Lung Cancer. 2020 Dec;150:70-75. doi: 10.1016/j.lungcan.2020.10.005. Epub 2020 Oct 14.
7
Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response.镥肽受体放射性核素治疗在诱导小肠神经内分泌肿瘤的长期肿瘤消退中的疗效：初始客观缓解后再次治疗的有利反应病例。
Oncol Res Treat. 2021;44(5):276-280. doi: 10.1159/000515859. Epub 2021 Apr 14.
8
The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo.丙戊酸治疗对放射性标记的奥曲肽摄取的影响：体内外观察到的差异
Pharmaceutics. 2022 Jan 12;14(1):173. doi: 10.3390/pharmaceutics14010173.
9
Somatostatin receptor imaging with [Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma.[镓]镓- DOTATATE正电子发射断层扫描/计算机断层扫描（PET/CT）对鼻咽癌患者进行生长抑素受体显像
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1360-1373. doi: 10.1007/s00259-021-05587-7. Epub 2021 Oct 19.
10
Clinical utility of Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity.¹⁷⁷Lu-DOTATATE肽受体放射性核素治疗在生长抑素受体阳性转移性甲状腺髓样癌患者中的临床应用：疗效评估、生存分析、预后变量及毒性研究
Head Neck. 2020 Mar;42(3):401-416. doi: 10.1002/hed.26024. Epub 2019 Nov 22.

引用本文的文献

1
Radiopharmaceuticals and their applications in medicine.放射性药物及其在医学中的应用。
Signal Transduct Target Ther. 2025 Jan 3;10(1):1. doi: 10.1038/s41392-024-02041-6.

本文引用的文献

1
EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities.EWSR1/FUS-CREB 融合定义了一种独特的恶性上皮样肿瘤，偏爱间皮衬里的腔隙。
Mod Pathol. 2020 Nov;33(11):2233-2243. doi: 10.1038/s41379-020-0646-5. Epub 2020 Aug 7.
2
Expanding the Phenotypic Spectrum of Mesenchymal Tumors Harboring the EWSR1-CREM Fusion.扩大具有 EWSR1-CREM 融合的间叶性肿瘤的表型谱。
Am J Surg Pathol. 2019 Dec;43(12):1622-1630. doi: 10.1097/PAS.0000000000001331.
3
Mesenchymal Tumors with EWSR1 Gene Rearrangements.
伴有EWSR1基因重排的间叶性肿瘤
Surg Pathol Clin. 2019 Mar;12(1):165-190. doi: 10.1016/j.path.2018.10.007.
4
Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells.生长抑素受体亚型的表达及选择性激活可诱导癌细胞的细胞周期停滞。
Oncol Lett. 2019 Feb;17(2):1723-1731. doi: 10.3892/ol.2018.9773. Epub 2018 Nov 28.
5
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
6
EWSR1 Fusions With CREB Family Transcription Factors Define a Novel Myxoid Mesenchymal Tumor With Predilection for Intracranial Location.EWSR1与CREB家族转录因子的融合定义了一种新的倾向于颅内定位的黏液样间叶性肿瘤。
Am J Surg Pathol. 2017 Apr;41(4):482-490. doi: 10.1097/PAS.0000000000000788.
7
A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs.一名转移性肉瘤患者用放射性标记的生长抑素类似物成功治疗。
Clin Nucl Med. 2016 Sep;41(9):705-7. doi: 10.1097/RLU.0000000000001288.
8
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.用[177Lu-DOTA0,Tyr3]奥曲肽对无功能胰腺神经内分泌肿瘤进行新辅助治疗。
J Nucl Med. 2015 Nov;56(11):1647-53. doi: 10.2967/jnumed.115.158899. Epub 2015 Aug 13.
9
Somatostatin receptors: from signaling to clinical practice.生长抑素受体：从信号转导到临床实践。
Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18.
10
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.诱导肽受体化学放射核素治疗使不可切除的胰腺和十二指肠神经内分泌肿瘤变得可切除的潜力。
Eur J Surg Oncol. 2012 Jan;38(1):64-71. doi: 10.1016/j.ejso.2011.08.129. Epub 2011 Sep 8.